Passive immunization experiments have established that antibodies (Abs) provide sterilizing immunity against infections with HIV and contribute to augmented responses to infection. Six epitopes have been identified that induce protective Abs, including sites in gp41 and gpl20, including the V3 loop, the CD4 binding domain, a CD4-induced epitope in the bridging sheet, and a carbohydrate epitope near the base of the V4 loop. Induction of Abs to each of these epitopes may ultimately be useful as a defensive shield against HIV infection, however, each of these epitopes presents a challenge to vaccine design. Anti-V3 Abs were initially thought to mediate only type-specific neutralization of T cell line-adapted viruses. However, new data show that, although type-specific anti-V3 Abs are induced early after immunization and infection, broadly neutralizing anti-V3 Abs also exist, and primary isolates can be efficiently neutralized with microgram amounts of several anti-V3 monoclonal antibodies (mAbs). Recent studies also suggested that the conformation of the V3 loop might be constrained because the V3 must interact with chemokine receptors, a theory now confirmed by our recent structural studies showing molecular mimicry between the V3 loop and structures in the physiologic ligands of CCR5 and CXCR4; this provides an explanation for the broad and potent cross-neutralizing activity displayed by several anti-V3 mAbs. These structural studies have been performed with anti-V3 mAbs that neutralize primary isolates from clades A, B and F. No human anti-V3 mAbs exist which consistently neutralize Clade C viruses, the HIV subtype that causes approximately 50% of the pandemic. Therefore, we propose in Aim 1 to produce human mAbs that recognize conformational epitopes of V3 from the cells of Clade C-infected subjects, use these mAbs to ascertain the structure of the Clade C V3 loop, and design V3 mimetic immunogens. These, and additional clade B-based V3 mimetic immunogens, will be used in Aim 2, in rabbits, to induce and focus the immune response on broadly neutralizing Abs to conserved conformational epitopes in the V3 loop. Finally, in Aim 3, we will examine how the intra- and inter-molecular interactions of gpl20 and gp41 affect neutralization sensitivity to anti-V3 mAbs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI036085-12
Application #
7081419
Study Section
Special Emphasis Panel (ZRG1-VACC (01))
Program Officer
Warren, Jon T
Project Start
1994-08-01
Project End
2009-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
12
Fiscal Year
2006
Total Cost
$638,312
Indirect Cost
Name
New York University
Department
Pathology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Li, Liuzhe; Wang, Xiao-Hong; Williams, Constance et al. (2015) A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site. Mol Immunol 66:364-74
Yu, Xuesong; Gilbert, Peter B; Hioe, Catarina E et al. (2012) Statistical approaches to analyzing HIV-1 neutralizing antibody assay data. Stat Biopharm Res 4:1-13
Agarwal, Alpna; Hioe, Catarina E; Swetnam, James et al. (2011) Quantitative assessment of masking of neutralization epitopes in HIV-1. Vaccine 29:6736-41
Changela, Anita; Wu, Xueling; Yang, Yongping et al. (2011) Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol 85:2524-35
Spurrier, Brett; Sampson, Jared M; Totrov, Maxim et al. (2011) Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120. Structure 19:691-9
Ringe, Rajesh; Sharma, Deepak; Zolla-Pazner, Susan et al. (2011) A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop. Virology 418:123-32
Musich, Thomas; Peters, Paul J; Duenas-Decamp, Maria José et al. (2011) A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection. J Virol 85:2397-405
Gorny, Miroslaw K; Sampson, Jared; Li, Huiguang et al. (2011) Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure. PLoS One 6:e27780
Shmelkov, Evgeny; Nadas, Arthur; Swetnam, James et al. (2011) Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects. PLoS One 6:e27279
Zolla-Pazner, Susan; Kong, X-P; Jiang, Xunqing et al. (2011) Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J Virol 85:9887-98

Showing the most recent 10 out of 88 publications